![](https://investorshub.advfn.com/uicon/496411.png?cb=1505403973)
Wednesday, July 10, 2024 1:41:03 PM
The Phantom Pain study (which has already been published) has similar Quality Control warnings:
https://clinicaltrials.gov/study/NCT05392803?tab=history&a=6#version-content-panel
Regarding gender: there were no hypotheses about gender in the protocol so gender is not a factor. Ilfeld could cherry-pick the results by gender and/or by indication but the CMS would not accept cherry-picked results.
Bottom line: BIEL can't show this to the CMS. BIEL will have to show the CMS their other data and hope the CMS is generous, which they might well be, considering the political pressure to reduce opioid use.
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM